source
- Analysts warn that PD-1/VEGF bispecific drugs may be better suited for liver cancer than lung cancerMany drugmakers have poured billions into PD-1/VEGF bispecific antibodies after ivonescimab beat Keytruda in a 2024 lung‑cancer trial, sparking a wave of deals and development programs. A recent C…
- Biotech lobby groups in Washington push to keep Chinese low-cost drug pipeline open amid rising anti-China proposalsWashington biotech lobby groups are working to ensure a steady flow of affordable medicines that originate from Chinese manufacturers. These groups have become aware that they are encountering voc…